Pictured above: Participants at one of our workshops at LSE

Patient Academy at the London School of Economics
Next Course: February 23 and 24 2015

REGISTRATION NOW CLOSED

DOWNLOAD THE DRAFT PROGRAMME HERE 

There is increasing emphasis on ‘patient centred healthcare’ and greater involvement of patient groups in policy setting at all levels. However, it is clear that not all patient groups are sufficiently skilled to take full advantage of the opportunities offered to them to contribute effectively to developing policy.

Training available to patient groups is generally focused on aspects of running a patient organisation effectively and ensuring that the requirements of the national charity commission or equivalent are met. What has been missing is training on aspects of healthcare that are impacting on the delivery of high quality care to patients.

Yet, if patient groups are to effectively advocate for better care for the patients they serve (and, directly or indirectly, the patients’ caregivers) they need to be skilled in a range of topics in order to hold their own in discussions with policy makers and healthcare delivery organisations.

The LSE and EFNA have worked together for many years to deliver training to patient groups on health technology assessment (HTA) and more recently on Pharmaceutical Pricing, Access and Reimbursement. The next workshop, taking place on February 24 and 25 in London, will focus on this topic.

The aim will be to equip  participants with the knowledge and skills they need to be actively involved in influencing regulatory decision-making in relation to medical technologies/pharmaceuticals. By attending this course, participants will obtain insights on: (a) how pharmaceuticals fit within the overall health care system; (b) how different countries in Europe and beyond pay for pharmaceuticals; (c) what are the most salient regulations addressing coverage/access and how these affect patient access; (d) how stakeholders – including patients – participate in the decision-making process. Topics include:

• Rate of Return Regulations
• Price Referencing and Tendering
• Patient Access Schemes
• Generic Pharmaceutical Policy
• Risk Sharing
• Adherence to Medicines
• Value Based Pricing
• Prescribing Policies and Incentives